BTIG Reiterates Buy Rating on Theravance Biopharma (TBPH) amid Yupelri growth

March 19, 2026 4:40 PM

BTIG analyst Julian Harrison reiterated a Buy rating and $21.00 price target on Theravance Biopharma (NASDAQ: TBPH)The analyst commented, "4Q25 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found